Euroapi (XPAR:EAPI) Asset Impairment Charge: €0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:EAPI Euroapi SA XPAR:EAPI
59 GF Score
Price €1.23
GF Value €2.87
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Euroapi Asset Impairment Charge?

Euroapi XPAR:EAPI -2.70% 59 Asset Impairment Charge is €0.0 Mil as of Dec. 2025. GuruFocus rates XPAR:EAPI with a GF Score™ of 59/100 and a GF Value™ of €2.87 (Possible Value Trap). The stock has 6 warning signs investors should review.

Euroapi's Asset Impairment Charge for the six months ended in Dec. 2025 was €0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Euroapi Asset Impairment Charge Related Terms

Euroapi Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Euroapi's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Euroapi Asset Impairment Charge Chart

Euroapi Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Euroapi Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:EAPI
59GF Score
Euroapi SA XPAR:EAPI
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Euroapi Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

What does a Asset Impairment Charge of €0.0 Mil mean?
Euroapi (XPAR:EAPI) has a Asset Impairment Charge of €0.0 Mil as of Dec. 2025.
Is Euroapi's Asset Impairment Charge too high?
Euroapi's current Asset Impairment Charge is €0.0 Mil. Overall, Euroapi has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's Asset Impairment Charge compare to ZTS and UTHR?
Euroapi's Asset Impairment Charge of €0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Drug Manufacturers company?
A good Asset Impairment Charge depends on the Drug Manufacturers industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Euroapi's current Asset Impairment Charge is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (XPAR:EAPI) is currently considered Possible Value Trap. The stock's GF Value™ is €2.87, compared to a current price of €1.23 — trading 57.3% below its estimated fair value. The current Asset Impairment Charge is €0.0 Mil. Euroapi's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Euroapi (XPAR:EAPI), the current Asset Impairment Charge is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Euroapi (XPAR:EAPI) Overvalued in 2026?

Based on GuruFocus' analysis, Euroapi stock appears to be undervalued. The current stock price of €1.23 is trading 57.3% below its estimated GF Value™ of €2.87. GuruFocus considers Euroapi to be Possible Value Trap.

Key valuation signals for XPAR:EAPI:

  • Asset Impairment Charge: €0.0 Mil
  • GF Value™: €2.87 vs. price of €1.23 (57.3% below fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the XPAR:EAPI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Euroapi Business Description

Other Exchanges EAPIF:USA0EAP:UK940:Germany
Address 32 rue Alexandre Duma, Paris, FRA, 75011
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
59GF Score

Get the complete analysis for XPAR:EAPI

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.23
Price
€2.87
GF Value